Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Urelumab by Bristol-Myers Squibb for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Urelumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
Data Insights
Urelumab by Bristol-Myers Squibb for Gliosarcoma: Likelihood of Approval
Urelumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I...